Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch

doi:10.3748/wjg.v31.i26.109285

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (853)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

HTML

552

Figures (1-4)

Tables (1-5)

Sum=681

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

116

Sum=124

Jul 14, 2025 (publication date) through Jul 28, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Jul 14, 2025; 31(26): 109285
Published online Jul 14, 2025. doi: 10.3748/wjg.v31.i26.109285

Table 1 Baseline demographic profiles and characteristics, mean ± SE

Mark	Total (n = 53)	TDF (n = 14)	TMF (n = 39)	P value
Gender (M/F)	36/17	8/6	28/11	0.314
Age	36.89 ± 1.44	34.50 ± 1.95	37.74 ± 1.83	0.327
BMI 0 week	22.83 ± 0.67	22.01 ± 1.02	23.16 ± 0.85	0.448
WBC 0 week	6.13 ± 0.22	6.27 ± 0.45	6.08 ± 0.26	0.715
Hb 0 week	149.02 ± 2.06	147.79 ± 3.88	149.46 ± 2.45	0.723
PLT 0 week	214.62 ± 10.01	234.00 ± 15.58	207.67 ± 12.31	0.250
ALT 0 week	129.10 ± 17.09	176.42 ± 53.02	112.12 ± 13.01	0.097
AST 0 week	79.79 ± 9.70	99.85 ± 28.31	73.10 ± 8.91	0.236
Cr 0 week	65.84 ± 2.08	67.25 ± 5.17	65.37 ± 2.22	0.699
CLCR 0 week	116.45 ± 3.46	112.04 ± 7.11	117.91 ± 3.98	0.468
PHOS 0 week	1.06 ± 0.03	1.09 ± 0.07	1.05 ± 0.03	0.459
GLU 0 week	4.97 ± 0.11	4.73 ± 0.11	5.06 ± 0.14	0.176
TG 0 week	1.06 ± 0.07	1.15 ± 0.20	1.03 ± 0.06	0.477
CHOL 0 week	4.76 ± 0.15	4.77 ± 0.20	4.76 ± 0.19	0.984
HDL 0 week	1.46 ± 0.05	1.45 ± 0.10	1.46 ± 0.06	0.960
LDL 0 week	2.74 ± 0.11	2.74 ± 0.17	2.74 ± 0.14	0.989
FIB-4 0 week	1.46 ± 0.18	1.28 ± 0.29	1.52 ± 0.22	0.576
CAP 0 week	204.50 ± 5.74	212.07 ± 13.44	201.38 ± 5.99	0.403
RNA 0 week	4.14 ± 0.39	3.99 ± 0.86	4.18 ± 0.44	0.845
DNA 0 week	6.81 ± 0.17	7.20 ± 0.28	6.67 ± 0.21	0.181
miR3 0 week	5.38 ± 0.29	5.33 ± 0.60	5.40 ± 0.34	0.919
HBsAg 0 week	2.94 ± 0.12	3.12 ± 0.25	2.88 ± 0.14	0.381
HBeAg 0 week	0.98 ± 0.27	1.33 ± 0.54	0.85 ± 0.31	0.441

TMF: Tenofovir amibufenamide; TDF: Tenofovir disoproxil fumarate; M: Male; F: Female; BMI: Body mass index; WBC: White blood cells; Hb: Hemoglobin; PLT: Platelet; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatinine; CLCR: Creatinine clearance; PHOS: Phosphorus; GLU: Glucose; TG: Triglycerides; CHOL: Cholesterol; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; FIB-4: Fibrosis-4; CAP: C-reactive protein; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; miR3: Hepatitis B virus-microRNA-3.

Citation: Zeng ZH, Liu JQ, Zhang M, Qiu CL, Xu ZY. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. World J Gastroenterol 2025; 31(26): 109285
URL: https://www.wjgnet.com/1007-9327/full/v31/i26/109285.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i26.109285